Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection.
The effect of liposome delivery on the controlled release and therapeutic efficacy of ciprofloxacin against intracellular Francisella tularensis infection in vivo was evaluated in this study. Ciprofloxacin was encapsulated in small unilamellar vesicles by a remote loading procedure using an ammonium sulfate gradient. This procedure produced uniform sized liposomes (100 nm) with an entrapment rate of 90+/-3.5%. Following administration of unencapsulated or liposome-encapsulated ciprofloxacin by intravenous injection or aerosol inhalation, levels of ciprofloxacin in sera, lungs, liver and spleen were determined using 14C-ciprofloxacin as radiotracer for ciprofloxacin. Intravenous injection of liposome-encapsulated ciprofloxacin resulted in higher serum levels of drug in serum, as well as increased drug retention in lungs, liver and spleen, compared to that of free encapsulated drug. Aerosol administration of liposome-encapsulated ciprofloxacin by jet nebulization resulted in significantly higher drug levels and prolonged drug retention in the lower respiratory tract compared to the free drug. Aerosol inhalation of liposome-encapsulated ciprofloxacin, given either prophylactically or therapeutically, provided complete protection to mice against a pulmonary lethal infection model of F. tularensis. In contrast, ciprofloxacin given in its free form, was ineffective. These results suggest that liposome encapsulation of ciprofloxacin enhances drug delivery to the primary site of infection and results in increasing therapeutic efficacy against F. tularensis.
Chemical and Biological Defence Section, Defence R&D Canada-Suffield, Box 4000 Station Main, Medicine Hat, Alberta, Canada T1A 8K6. jonathan.wong@drdc-rddc.gc.ca
Jonathan P
JP
Wong
Huiming
H
Yang
Karen L
KL
Blasetti
Glen
G
Schnell
John
J
Conley
Lawrence N
LN
Schofield
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D005604:Francisella tularensis; D007275:Injections, Intravenous; D008081:Liposomes; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000378:metabolism; D015996:Survival Rate; D014018:Tissue Distribution; D014406:Tularemia / Q000188:drug therapy* / Q000401:mortality
D000890:Anti-Infective Agents; D003692:Delayed-Action Preparations; D008081:Liposomes; D002939:Ciprofloxacin